• The two sides plan to carry out industry-university-research transformation cooperation in liver angiology technology
• Jointly unveil the “Medical Engineering Cross-Innovation Workstation” with a team of academicians
• In the future, the scope of cooperation will be further expanded to areas such as accurate diagnosis and treatment of chronic liver disease and tumor intervention

HANGZHOU, April 15, 2024 /PRNewswire/ -- Recently, CHESS Liver Health Alliance and Siemens Healthcare jointly unveiled the “Medical Engineering Cross-Innovation Workstation”, empowered by Southeast University's National Medical Research, Obstetrics and Education Integration Innovation Platform.” The “Medical Engineering Cross-Innovation Workstation” will be launched at Siemens Healthcare's Shanghai Innovation Center. The two sides initially plan to focus on the discipline construction of chronic liver disease, explore the construction of a medical and engineering cross-innovation mechanism system, and promote the comprehensive promotion and clinical transformation of scientific and technological innovation achievements. Academician of the Chinese Academy of Sciences, head of the National Medical Research, Obstetrics and Education Integration Innovation Platform at Southeast University, Director of Zhongda Hospital Affiliated to Southeast UniversityTeng Gaojun, founder of CHESS, senior national talent, assistant director of Zhongda Hospital affiliated to Southeast UniversityQi Xiaolong, Secretary General of the National Medical Research, Obstetrics and Education Integration Innovation Platform, Southeast UniversityGu Xiaochun, President of Siemens Healthcare Greater China and member of the Global Leadership CommitteeWang Hao, General Manager of Siemens Healthcare Greater China Strategy and Business Development and Healthcare Enterprise Services and SolutionsJia Danlin, Head of Digital Medicine Division, Shanghai Siemens Medical Devices Co., Ltd.Mountain blueWait for the leaders of both sides to attend the unveiling ceremony.

Relying on the cutting-edge transformation facilities and extensive ecological network of Siemens Healthcare's Shanghai Innovation Center, and empowered by the Southeast University National Medical Research Obstetrics and Education Integration Innovation Platform, the two sides will further cooperate on the transformation of liver angiology technology, work together to promote industry-university-research transformation project cooperation in the field of liver, and create a new ecosystem of integrated industry-university-research development. On this basis, the two sides also plan to further build an innovation transformation salon exchange platform to promote the comprehensive promotion and application transformation of medical science and technology innovation achievements and accelerate academic research and technological progress in the field of liver health.

Academician Teng GaojunHe said, “The establishment of the 'Medical Engineering Interdisciplinary Innovation Workstation' has not only built a cutting-edge platform for deep collaboration and joint research and development between the two sides, but has also injected strong new impetus into innovation and development in the interdisciplinary field of medical engineering. We expect the two sides to take solid steps on the path of chronic liver disease discipline construction, jointly explore new paths for the construction of a cross-medical engineering innovation mechanism system, promote the widespread application and transformation of scientific and technological innovation achievements in clinical practice, and benefit patients.”

As we all know, chronic liver disease seriously threatens people's lives and health. Chronic liver disease progresses through various stages, from liver fibrosis and cirrhosis to liver cancer. Therefore, early intervention and full management are particularly critical. In the past five years, China accounted for nearly half of the world's new cases of liver cancer. The overall five-year net survival rate of liver cancer patients in China was only 14.1%^[1], constituting a serious burden of disease.

Siemens Healthcare has always focused on diseases with a high incidence rate in Chinese society, hoping to help solve the most urgent medical needs through disease-centered comprehensive solutions. During this year's CMEF, Siemens Healthcare solemnly launched a full-life cycle solution for liver cancer, combining innovative technologies and products from Siemens Healthcare and Varian to help improve the accuracy of the whole process of “prevention, screening, diagnosis, treatment and treatment” of liver cancer, optimize the liver cancer diagnosis and treatment process, improve the efficiency of liver cancer diagnosis and treatment, and ultimately help improve overall survival rate. Taking digital advantages as an example, Siemens Healthcare's image post-processing platform syngo.via breaks through the limitations of traditional pre-surgical evaluation, realizes holographic bionic reality rendering of liver structures, facilitates doctors to simulate surgery before surgery, and performs virtual liver resection on “patient twins” to accurately plan the scope and path of resection and minimize post-operative complications. Siemens Healthcare's digital 5G remote application can solve the time and space challenges faced in the liver cancer diagnosis and treatment process, help hospitals more conveniently implement the MDT diagnosis and treatment service model, enhance radiation reduction in regional medical centers, and enhance the liver cancer diagnosis and treatment capabilities of primary hospitals.

^[1] The Committee for the Prevention and Control of Hepatobiliary and Pancreatic Diseases of the Chinese Society of Preventive Medicine, the Liver Disease Professional Committee of the Chinese Society of Research Hospitals, the Hepatology Branch of the Chinese Medical Association, etc. Guidelines for stratified screening and monitoring of primary liver cancer (2020 edition) [J]. Chinese Journal of Hepatology, 2021, 29 (1): 25-40. DOI:10.3760/cma.j.cn112152-20201109-00970.

About Siemens Healthcare 

An innovative environment for every life. Siemens Healthcare is a leading global provider of medical devices, solutions and services, operating in more than 180 countries and directly operating in more than 70 countries. Siemens Healthcare is comprised of Siemens Healthcare AG (Frankfurt Stock Exchange code: SHL) and its subsidiaries. As a leading medical technology company, Siemens Healthcare is committed to improving access to quality medical resources while overcoming deadly diseases that threaten human health. Siemens Healthcare's business covers fields such as medical imaging, in vitro diagnosis, cancer diagnosis and treatment, and minimally invasive treatment, and strengthens its various businesses through digital technology and artificial intelligence. As of fiscal year 2023 (September 30, 2023), Siemens Healthcare had approximately 71,000 employees worldwide and revenue of approximately €21.7 billion. For more information, visit